Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

Phase 2 Not yet recruiting 135 enrolled CHA Vaccine Institute Co., Ltd.

RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.

Timeline

Start: 2026-04
Primary completion: 2027-01
Completion: 2027-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CVI-VZV-001	Vaccine	—	Intramuscular
Comparator	VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E	Vaccine	—	Intramuscular

Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

Summary

Timeline

Drugs

Indications